Century Therapeutics, Inc. business relationships
Companies named in Century Therapeutics, Inc.’s 10-K filed 2026-03-12, and public companies whose annual reports name Century Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 2% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Century Therapeutics, Inc.’s annual report 3
“Our revenues to date were generated through our collaboration, option and license agreement with Bristol-Myers Squibb, which was terminated in March 2025.” SEC filing
“Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $ 100,000 and agreed to pay an exercise fee upon the exercise of the License Option ("Licensed Program" and product candidates developed under a Licensed Program, "Licensed Products").” SEC filing
“In January 2019, we entered into a non-exclusive license agreement with Inscripta, Inc. Under the license agreement, we obtained a non-exclusive, royalty-free, irrevocable license to a patent portfolio covering the composition, production, and use of CRISPR-MAD7, a novel gene-editing CRISPR endonucl...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.